Q&A: How organoids could make gene therapy trials safer by identifying hidden risks early on

Ryuji Morizane, MD, Ph.D., of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author of a new paper published in Signal Transduction and Targeted Therapy, titled “AAV for gene therapy drives a nephrotoxic response via NFκB in kidney organoids.”

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup